Patients fulfilling LLDAS, LLDAS5 and DORIS criteria at baseline evaluation and during follow-up
| Baseline 2012 | 2013 | 2014 | 2015 | Last visit 2016 | Sustained 100% | Sustained 50% | |
| LLDAS | 72 (63.1%) | 72 (63.1%) | 80 (70.2%) | 77 (68.1%) | 86 (74.8%) | 42 (36.5%) | 81 (70.4%) |
| LLDAS5 | 71 (61.6%) | 69 (60%) | 80 (70.2%) | 77 (68.1%) | 85 (73.9%) | 41 (35.6%) | 79 (68.6%) |
| RONT | 57 (49.6%) | 53 (46%) | 60 (52.1%) | 55 (47.8%) | 55 (47.8%) | 25 (21.7%) | 55 (47.8%) |
| ROFT | 12 (10.4%) | 14 (12.1%) | 18 (15.6%) | 23 (20%) | 23 (20%) | 6 (5.2%) | 17 (14.8%) |
| Complete RONT | 33 (28.7%) | 30 (26%) | 31 (26.9%) | 22 (19.1%) | 24 (20.8%) | 9 (7.8%) | 24 (20.9%) |
| Complete ROFT | 2 (1.7%) | 4 (3.5%) | 8 (6.9%) | 8 (6.9%) | 9 (7.8%) | 1 (0.8%) | 4 (3.5%) |
DORIS, Definition of Remission in SLE; LLDAS, lupus low disease activity state; LLDAS5, LLDAS with a GC dosage ≤5; ROFT, remission OFF treatment; RONT, remission ON treatment.